Methyltransferase like 7B is upregulated in sepsis and modulates lipopolysaccharide-induced inflammatory response and

Dan Huang1,2, Hai Yan1,3

  • 1Clinical Medical College of Chengdu Medical College, Chengdu, China.

Bioengineered
|May 23, 2022
PubMed

Insights

Methyltransferase like 7B (METTL7B) is upregulated in sepsis patients and regulates inflammatory responses in macrophages. METTL7B shows diagnostic potential and may be a therapeutic target for sepsis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pathophysiology

Background:

  • Macrophages are key regulators of inflammatory responses in sepsis.
  • Methyltransferase like 7B (METTL7B) is involved in various pathophysiological conditions.
  • The role of METTL7B in sepsis pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the expression and function of METTL7B in sepsis.
  • To determine if METTL7B plays a role in macrophage-mediated inflammatory responses during sepsis.
  • To explore METTL7B as a potential diagnostic and therapeutic target for sepsis.

Main Methods:

  • Analysis of transcriptomic data from septic patients and healthy donors.
  • Quantitative reverse transcription PCR (RT-qPCR) on patient samples.
  • In vitro studies using murine bone marrow-derived macrophages (BMDMs) stimulated with lipopolysaccharide (LPS).
  • Overexpression and knockdown of METTL7B in BMDMs.
  • Evaluation of inflammatory cytokines and macrophage polarization.
  • Validation in a septic mouse model.

Main Results:

  • METTL7B expression was significantly upregulated in septic patients' blood and PBMCs, indicating diagnostic potential.
  • LPS treatment induced METTL7B expression in BMDMs in a time- and dose-dependent manner.
  • Modulating METTL7B levels affected LPS-induced inflammatory cytokine production and macrophage polarization.
  • METTL7B's role was confirmed in a septic mouse model.

Conclusions:

  • METTL7B is upregulated in sepsis and contributes to the immunopathogenesis by modulating macrophage-mediated inflammatory responses.
  • METTL7B may serve as a valuable diagnostic biomarker for sepsis.
  • METTL7B represents a potential therapeutic target for managing sepsis.